联合治疗公司

最新新闻

• 评级变动
  J.P. Morgan Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $687
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  BTIG Upgrades United Therapeutics(UTHR.US) to Buy Rating, Announces Target Price $728
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• United Therapeutics(UTHR.US) Officer Sells US$5.08 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/10
• United Therapeutics(UTHR.US) Officer Sells US$5.22 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• J.P. Morgan Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $710
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $704
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $677
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $708
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $700
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $677
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Announces Target Price $685
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $738
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $704
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $660
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Morgan Stanley Maintains United Therapeutics(UTHR.US) With Hold Rating, Raises Target Price to $566
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• BofA Securities Maintains United Therapeutics(UTHR.US) With Hold Rating, Cuts Target Price to $559
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $675
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $700
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Cantor Fitzgerald Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $700
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Goldman Sachs Initiates United Therapeutics(UTHR.US) With Sell Rating, Announces Target Price $321
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $714
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 评级变动
  BofA Securities Maintains United Therapeutics(UTHR.US) With Hold Rating, Cuts Target Price to $613
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 评级变动
  Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $700
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• United Therapeutics(UTHR.US) Officer Sells US$4.52 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/29

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。